🇺🇸 FDA
Pipeline program

ARQ-234

ARQ-234-131

Phase 1 mab active

Quick answer

ARQ-234 for Atopic Dermatitis (AD) is a Phase 1 program (mab) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcutis Biotherapeutics
Indication
Atopic Dermatitis (AD)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials